CME/CE

Guest: Joyce O'Shaughnessy, MD By 2040, the global breast cancer burden is expected to increase by 40%, resulting in more than 3 million new cases and 1 million deaths per year. Approximately 65% of cases among women less than 50 years of age and 75% of cases among women over 50 years of age are classified as HR+/HER2-. Although endocrine therapy is employed as standard-of-care treatment for...

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney dise...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidn...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney d...

Host: Richard Johnson, MD This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and...

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Guru...

Host: Nirav Y. Raval, MD, FACC Guest: Gurusher Panjrath, MD, FACC, FAHA, FHFSA This program is no longer available for credit. Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Guru...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci This program is no longer available for credit. Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and impr...

Host: Lee P. Shulman, MD, FACMG, FACOG Guest: Roberto Romero, MD, DMedSci This program is no longer available for credit. Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and impr...